Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Etiological Profile of Galactorrhoea.

Indian journal of endocrinology and metabolism·2018

Same author

Impairment of Health-related Quality of Life among Indian Patients with Hypothyroidism.

Indian journal of endocrinology and metabolism·2018

Same author

Normative Values for Electrochemical Skin Conductance Measurements for Quantitative Assessment of Sudomotor Function in Healthy Indian Adults.

Indian journal of endocrinology and metabolism·2018

Same author

Diabetes in the Elderly.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2018

Same author

Diabetic Painful Neuropathy and Restless Legs Syndrome in Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2018

Same author

Lipocrinology - the relationship between lipids and endocrine function.

Drugs in context·2018

Search research articles

Related Experiment Video

Updated: May 30, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Bromocriptine in type 2 diabetes mellitus.

C Shivaprasad¹, Sanjay Kalra

¹Department of Endocrinology, M. S. Ramaiah Hospital, Bangalore, India.

Indian Journal of Endocrinology and Metabolism

|August 18, 2011

Summary

This summary is machine-generated.

Bromocriptine quick-release (QR) is an FDA-approved medication for type 2 diabetes. This drug effectively lowers blood sugar and offers cardiovascular benefits with a favorable side effect profile.

Keywords:

Bromocriptine circadian rhythm diabetes insulin resistance quick release formulation

Related Experiment Videos

Last Updated: May 30, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Area of Science:

Endocrinology
Metabolic Disorders
Pharmacology

Background:

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and elevated blood glucose levels.
Current treatments for type 2 diabetes aim to improve glycemic control and reduce cardiovascular risk.
Bromocriptine, a dopamine agonist, has been repurposed for type 2 diabetes treatment due to its unique mechanism of action.

Purpose of the Study:

To evaluate the efficacy and safety of bromocriptine quick-release (QR) in patients with type 2 diabetes.
To investigate the mechanism of action of bromocriptine in improving glycemic control.
To assess the impact of bromocriptine-QR on cardiovascular risk factors.

Main Methods:

Randomized controlled trials (RCTs) were conducted to assess bromocriptine-QR efficacy.
Studies involved patients with type 2 diabetes, treated with bromocriptine-QR as monotherapy or in combination with other anti-diabetic agents.
Data on glycemic control (HbA1c), lipid profiles, and cardiovascular events were collected.

Main Results:

Bromocriptine-QR demonstrated a significant reduction in glycated hemoglobin (HbA1c) levels, ranging from 0.4% to 0.8%.
The drug was found to be well-tolerated at doses up to 4.8 mg daily, with nausea being the most common side effect.
Bromocriptine-QR has shown potential in reducing cardiovascular event rates in type 2 diabetes patients.

Conclusions:

Bromocriptine-QR is an effective and well-tolerated treatment option for type 2 diabetes.
Its novel mechanism of action, targeting hypothalamic circadian activities, offers a new therapeutic approach.
The drug's favorable side effect profile and cardiovascular benefits make it an attractive addition to the anti-diabetic medication arsenal.